Chuyển đồi thái EQ-5D-3L và EORTC QLQ-C30 ở bệnh nhân ung thư vú
Tóm tắt
Từ khóa
#Mapping #EQ-5D-3L #EORTC QLQ-C30 #breast cancer #health economics #quality of life assessment #cost-effectiveness analysisTài liệu tham khảo
Kim SH, Jo MW, Kim HJ, Ahn JH. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes. 2012;10(1):1–6. https://doi.org/10.1186/1477-7525-10-151.
Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Heal Qual Life Outcomes. 2014;12(1):180. https://doi.org/10.1186/s12955-014-0180-6.
Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ. 2010;11(4):427–34. https://doi.org/10.1007/s10198-010-0233-7.
Lee CF, Ng R, Luo N, Cheung YB. Development of conversion functions mapping the FACT-B Total score to the EQ-5D-5L utility value by three linking methods and comparison with the ordinary Least Square method. Appl Heal Econ Heal Policy. 2018;16(5):685–95. https://doi.org/10.1007/s40258-018-0404-8.
Gray LA, Wailoo AJ, Hernandez AM. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping. Value Heal. 2018;21(12):1399–405.
Rose M, Rice S, Craig D. Does methodological guidance produce consistency? A review of methodological consistency in breast Cancer utility value measurement in NICE single technology appraisals. PharmacoEconomics - Open. 2017;2(2):97–107. https://doi.org/10.1007/s41669-017-0040-5.
Wailoo A, Hernández M, Philips C, Brophy S, Siebert S. Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods. Value Heal. 2015;18(4):425–31. https://doi.org/10.1016/j.jval.2015.02.016.
Hernandez Alava M, Wailoo A, Wolfe F, Michaud K. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Mak. 2014;34(7):919–30. https://doi.org/10.1177/0272989X13500720.
Gray LA, Hernández Alava M, Wailoo AJ. Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma. Value Heal. 2018;21(6):748–57.
Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford knee score. Qual Life Res. 2013;22(3):683–94. https://doi.org/10.1007/s11136-012-0189-4.
EORTC Quality of Life. EORTC QLQ-C30 Scoring Manual, 3rd Edition. 2001. Available at https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf. ISBN 2-9300 64-22-6.
Kim EJ. K KS, Kang HY. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Qual Life Res. 2012;21(7):1193–203. https://doi.org/10.1007/s11136-011-0037-y.
Hernández Alava M, Wailoo A, Wolfe F, Michaud K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatol (UK). 2013;52(5):944–50. https://doi.org/10.1093/rheumatology/kes400.
Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Heal Technol Assess. 2014;18(9):1–224. https://doi.org/10.3310/hta18090.
Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping Functions in Health-Related Quality of Life: Mapping From Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L. Med Decis Making. 2015;35(7):912–26. https://doi.org/10.1177/0272989X15587497.
Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non–preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Heal [Internet]. 2017;20(1):18–27. Available from:. https://doi.org/10.1016/j.jval.2016.11.006.
Hernández Alava M, Wailoo AJ, Pudney S, Gray LA, Manca A. Mapping clinical outcomes to generic preference-based outcome measures : development and comparison of methods. Heal Technol Assess J [Internet]. 2020;24(34) Available from:. https://doi.org/10.3310/hta24340.
Woodcock F, Doble B. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L : an assessment of existing and newly developed algorithms. Med Decis Mak. 2018;38(8):954–67. https://doi.org/10.1177/0272989X18797588.
Krop IE, Kim S, Gonzalez-Martin A, LoRusso PM, Ferrero J, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–99. https://doi.org/10.1016/S1470-2045(14)70178-0.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI J Natl Cancer Inst. 1993;82(5):365–76. https://doi.org/10.1093/jnci/85.5.365.
Bjordal K, De Graeff A, Fayers P, Hammerlid E, Van Pottelsberghe C, Curran D, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck Cancer specific module (EORTC QLQ-H & N35) in head and neck patients. Eur J Cancer. 2000;36(14):1796–807. https://doi.org/10.1016/S0959-8049(00)00186-6.
Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108. https://doi.org/10.1097/00005650-199711000-00002.
Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Heal. 2012;15(3):550–61. https://doi.org/10.1016/j.jval.2011.12.014.
Wailoo A, Hernandez Alava M, Escobar MA. Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D. Health Qual Life Outcomes. 2014;12(1):37. https://doi.org/10.1186/1477-7525-12-37.
Hernandez Alava M, Wailoo AJ. Fitting adjusted limited dependent variable mixture models to EQ-5D. Stata J. 2015;15(3):737–50. https://doi.org/10.1177/1536867X1501500307.
Fayers P, Bottomley A. Quality of life research within the EORTC—the EORTC QLQ-C30. Eur J Cancer. 2002;38:125–33. https://doi.org/10.1016/S0959-8049(01)00448-8.
Doble B, Lorgelly P. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L : assessing the external validity of existing mapping algorithms. Qual Life Res. 2016;25(4):891–911. https://doi.org/10.1007/s11136-015-1116-2.